Solventum's second-quarter profit falls 70% on higher expenses
Aug 8 (Reuters) -3M spin-off Solventum's SOLV.N second-quarter profit fell more than 70% on Thursday, hurt by limited sales growth of its wound care and surgical sterilization products and higher expenses, as it navigates functioning as a newly independent company.
These were Solventum's first financial results as an independent company. Its first-quarter results were prepared on a "carve-out" basis from 3M's healthcare business.
In its first-quarter earnings, the company had warned that it expected stand-up functional expenses to increase for the rest of the year.
Total operating expenses rose about 11%, to $1.84 billion, for the second quarter.
Minnesota-based Solventum is one of the largest providers of sterilization devices, wound dressings, medical tape and other hospital consumables used by healthcare facilities.
Its net income fell over 70% in the reported quarter to $89 million, or 51 cents per share, from $321 million, or $1.86 per share, a year earlier.
Total net sales were $2.08 billion, almost flat compared to last year.
More than half of total sales in the second quarter came from Solventum's MedSurg business, which provides wound dressings and surgical equipment.
The medical equipment maker raised the per-share range of its current-year adjusted profit forecast to between $6.30 and $6.50, from its earlier range of $6.10 per share to $6.40 per share.
"We are starting from a solid foundation and remain focused on addressing historical underperformance and spin-related topics to unlock significant value creation over time," CEO Bryan Hanson said.
The company now expects full-year organic sales to be flat to up 1%. Its earlier organic sales forecast was flat to down 2%.
On an adjusted basis, Solventum earned $1.56 per share for the quarter ended June 30.
Reporting by Vaibhav Sadhamta; Editing by Pooja Desai
Eng oxirgi yangiliklar
Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.
Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi
Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.
